
Opinion|Videos|May 19, 2026
Ongoing Research With Zongertinib in NSCLC
Author(s)Joshua K. Sabari, MD
Zongertinib shows strong tolerance and 70%+ responses in HER2-mutant metastatic NSCLC, with a pivotal Phase III trial versus standard chemo-immunotherapy underway.
Advertisement
Episodes in this series

Joshua K. Sabari, MD, discusses exploring combination approaches as the next research step with zongertinib in patients with HER2 mutation–positive non–small cell lung cancer. He also discusses how ongoing research is specifically examining the role of zongertinib in patients with HER2 amplification and HER2 overexpression.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Lung Cancer News Roundup: June 2026
2
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
3
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































